List of Contributors |
|
xi | |
Foreword |
|
xiii | |
Preface |
|
xv | |
1 The Human Genome |
|
|
|
|
1 | (1) |
|
Hereditary Factors, Genes, Genetics, and Genomics |
|
|
1 | (1) |
|
Structure and Organization of Nucleic Acids |
|
|
2 | (3) |
|
Human Genome Variation and Human Disease |
|
|
5 | (3) |
|
Measuring Genetic and Genomic Variation |
|
|
6 | (1) |
|
Genome Variation and Human Disease |
|
|
7 | (1) |
|
|
8 | (1) |
|
Functional Genomics, Transcriptomics, and Proteomics |
|
|
9 | (1) |
|
Translational Human Genomics |
|
|
10 | (1) |
|
Human Genomics for Socioeconomic Development |
|
|
11 | (1) |
|
|
12 | (1) |
|
|
12 | (3) |
2 Genomic Technologies in Medicine and Health: Past, Present, and Future |
|
|
|
|
|
15 | (1) |
|
|
16 | (1) |
|
Computational and Information Technologies |
|
|
16 | (1) |
|
Applications of Genomic Technologies |
|
|
17 | (1) |
|
The Microbiome and Human Health |
|
|
18 | (1) |
|
|
18 | (1) |
|
The Microbiome and Oral Health |
|
|
18 | (1) |
|
The Microbiome and Gastrointestinal Health |
|
|
18 | (1) |
|
The 1000 Genomes Project and Structural Variations in the Human Genomes |
|
|
18 | (1) |
|
Noninvasive Prenatal Testing by Sequencing of Cell-Free Fetal DNA in the Maternal Blood |
|
|
19 | (1) |
|
Prenatal Diagnosis by Whole Genome Sequencing of "Jumping Libraries" |
|
|
19 | (1) |
|
|
20 | (1) |
|
Genome Sequencing in Newborn Healthcare |
|
|
21 | (1) |
|
Genome Sequencing in Other Research Areas |
|
|
22 | (1) |
|
The Cancer Genome Atlas and Cancer Genomics |
|
|
22 | (1) |
|
|
22 | (1) |
|
|
23 | (2) |
|
Development of Targeted Therapeutics for Genetic Disorders |
|
|
23 | (1) |
|
Development of Targeted Therapeutics for Cancers |
|
|
24 | (1) |
|
Genomic Profiling and Counseling |
|
|
24 | (1) |
|
The Precision Medicine Initiative |
|
|
24 | (1) |
|
Policy and Regulatory Issues |
|
|
25 | (1) |
|
|
25 | (1) |
|
|
25 | (4) |
3 Genomic Databases, Access Review, and Data Access Committees |
|
|
|
|
|
|
29 | (1) |
|
Underlying Principles, Policies, and Guidelines |
|
|
30 | (1) |
|
Examples of Controlled-Access Databases and Pertinent Data Access Committees |
|
|
30 | (2) |
|
European Genome-phenome Archive |
|
|
30 | (1) |
|
Database of Genotypes and Phenotypes |
|
|
31 | (1) |
|
Ethical and Legal Challenges |
|
|
32 | (2) |
|
|
32 | (1) |
|
Oversight Mechanisms on Downstream Uses and Enforceability |
|
|
33 | (1) |
|
Data Producers and Data Users' Interests and Benefits |
|
|
33 | (1) |
|
|
34 | (1) |
|
|
34 | (1) |
|
|
34 | (3) |
4 Diagnostic Genomics and Clinical Bioinformatics |
|
|
|
|
|
|
37 | (5) |
|
Current Clinical Practice: Diagnosis |
|
|
37 | (1) |
|
|
37 | (1) |
|
|
38 | (1) |
|
|
38 | (1) |
|
|
39 | (1) |
|
|
39 | (1) |
|
Diagnostic Testing Strategy |
|
|
39 | (1) |
|
Inherited Cardiac Conditions |
|
|
40 | (1) |
|
Hypertrophic Cardiomyopathy |
|
|
40 | (1) |
|
|
40 | (1) |
|
|
41 | (1) |
|
Deciphering Developmental Disorders |
|
|
41 | (1) |
|
The UK100K Genomes Project: Large-Scale Implementation of Whole Genome Sequencing |
|
|
42 | (6) |
|
|
42 | (1) |
|
|
42 | (1) |
|
|
43 | (1) |
|
|
43 | (1) |
|
Interpretation of DNA Sequence Variants |
|
|
44 | (1) |
|
Protein-Altering Variants |
|
|
45 | (1) |
|
Variants Causing Aberrant Messenger RNA Splicing |
|
|
45 | (1) |
|
|
45 | (1) |
|
Inheritance and Mutation Type |
|
|
45 | (1) |
|
|
45 | (1) |
|
Mutational Mechanism and Variant Spectrum |
|
|
46 | (1) |
|
|
46 | (1) |
|
|
46 | (1) |
|
|
46 | (1) |
|
|
47 | (1) |
|
Online Mendelian Inheritance in Man |
|
|
47 | (1) |
|
|
47 | (1) |
|
|
48 | (1) |
|
|
48 | (1) |
|
|
48 | (3) |
5 Epigenetics and Epigenomics in Human Health and Disease |
|
|
|
|
51 | (1) |
|
Epigenotype and Regulation of Gene Expression |
|
|
51 | (2) |
|
Epigenotypes and Human Disease |
|
|
53 | (9) |
|
Trinucleotide Repeats and Human Disease |
|
|
54 | (1) |
|
|
54 | (1) |
|
|
55 | (1) |
|
|
56 | (1) |
|
Facioscapulohumeral Dystrophy |
|
|
57 | (2) |
|
Immunodeficiency, Centromeric Region Instability, and Facial Anomalies Syndrome: Genetic Mutations Causing Methylation |
|
|
59 | (1) |
|
|
60 | (1) |
|
alpha-Thalassemia X-Linked Mental Retardation Syndrome |
|
|
61 | (1) |
|
Epigenetic Mechanisms in Cancer |
|
|
62 | (1) |
|
|
63 | (1) |
|
|
63 | (1) |
|
|
63 | (12) |
6 Mitochondrial Genomics: Emerging Paradigms and Challenges |
|
|
|
|
|
|
|
75 | (1) |
|
Nongenetic Diagnostics for Mitochondrial Dysfunction |
|
|
75 | (3) |
|
|
78 | (1) |
|
DNA Testing, Next Generation Sequencing, and Mitochondrial Disease Diagnosis |
|
|
79 | (1) |
|
Next Generation Sequencing |
|
|
80 | (1) |
|
Next Generation Sequencing-Based Diagnostic Assay Design for Mitochondrial Disorders |
|
|
80 | (1) |
|
Translational Advancements |
|
|
81 | (3) |
|
Semantic Data Standards for Community Collaboration |
|
|
84 | (1) |
|
|
85 | (1) |
|
|
85 | (1) |
|
|
86 | (3) |
7 The Significance of Metabolomics in Human Health |
|
|
|
|
|
|
89 | (1) |
|
Metabolomics in Human Diseases |
|
|
90 | (3) |
|
|
93 | (1) |
|
Group Discrimination (Diagnosis) |
|
|
93 | (1) |
|
Inborn Metabolic Disorders |
|
|
93 | (1) |
|
|
94 | (1) |
|
Biomarkers for Psychiatric Diseases |
|
|
94 | (1) |
|
Metabolomics in Environmental and Public Health |
|
|
95 | (1) |
|
|
96 | (1) |
|
|
96 | (1) |
|
|
97 | (1) |
|
|
98 | (1) |
|
|
98 | (3) |
8 Microbial Genomics: Diagnosis, Prevention, and Treatment |
|
|
|
|
101 | (1) |
|
|
101 | (2) |
|
Treatment and Diagnostics |
|
|
103 | (2) |
|
|
105 | (2) |
9 A Metagenomic Insight Into the Human Microbiome: Its Implications in Health and Disease |
|
|
|
|
|
107 | (1) |
|
|
107 | (2) |
|
Human-Associated Microflora |
|
|
109 | (1) |
|
Alterations in the Healthy Human Microbiome: Association With Diseases |
|
|
110 | (1) |
|
|
110 | (1) |
|
|
111 | (1) |
|
|
111 | (4) |
|
Diseases Associated With Variation in the Gut Microbial Community |
|
|
112 | (3) |
|
Novel Therapeutic Strategies Based on the Human-Associated Microbiome |
|
|
115 | (1) |
|
|
116 | (1) |
|
|
117 | (1) |
|
List of Acronyms and Abbreviations |
|
|
117 | (1) |
|
|
117 | (4) |
10 Pharmacogenetics and Pharmacogenomics |
|
|
|
|
|
121 | (1) |
|
Pharmacogenomic Information in Drug Labeling |
|
|
122 | (2) |
|
Pharmacogenetic Guidelines |
|
|
124 | (1) |
|
Pharmacogenetic Study Design |
|
|
124 | (2) |
|
|
126 | (7) |
|
|
133 | (1) |
|
|
134 | (5) |
11 Medical and Health Aspects of Genetics and Genomics |
|
|
|
|
139 | (2) |
|
|
141 | (1) |
|
Mendelian (Single-Gene) Disorders |
|
|
142 | (1) |
|
Polygenic or Multifactorial Disorders |
|
|
142 | (2) |
|
Mitochondria! Genetic Disorders |
|
|
144 | (1) |
|
|
145 | (12) |
|
Disorders of Genomic Imprinting: Epigenetic Diseases |
|
|
145 | (5) |
|
Disorders of the Genome Architecture |
|
|
150 | (5) |
|
Disorders With Trinucleotide (Triplet) Repeats |
|
|
155 | (1) |
|
|
156 | (1) |
|
Disease Spectrum, Biological Pathways, and Genotypes |
|
|
157 | (2) |
|
|
159 | (1) |
|
|
159 | (2) |
12 Content and Variation of the Human Genome |
|
|
|
Introduction: "The Genome Anatomy" |
|
|
161 | (9) |
|
|
165 | (1) |
|
Noncoding, RNA-Only Genes |
|
|
166 | (2) |
|
Regions of Transcription Regulation |
|
|
168 | (1) |
|
Conserved Elements Not Included in the Previous Categories |
|
|
168 | (1) |
|
|
168 | (1) |
|
|
169 | (1) |
|
Special Genomic Structures Containing Selected Repeats |
|
|
170 | (6) |
|
|
170 | (1) |
|
|
171 | (1) |
|
Short Arms of Human Acrocentric Chromosomes |
|
|
171 | (1) |
|
|
172 | (1) |
|
|
172 | (4) |
|
Genome Variation as a Laboratory Tool to Understand the Genome |
|
|
176 | (1) |
|
|
176 | (3) |
13 Spectrum of Genetic Diseases and Management |
|
|
|
|
179 | (1) |
|
Molecular Approach to Genetic Disease Nosology |
|
|
179 | (1) |
|
From Marfan Syndrome to Fibrillinopathies |
|
|
180 | (4) |
|
Diagnosis of Marfan Syndrome |
|
|
182 | (1) |
|
|
182 | (1) |
|
Management of Marfan Syndrome |
|
|
183 | (1) |
|
|
183 | (1) |
|
The Emergence of RASopathies |
|
|
184 | (2) |
|
Malignancy Risk in RASopathies |
|
|
185 | (1) |
|
Making a Diagnosis of a Genetic Disorder in the Era of Molecular Pathways |
|
|
186 | (1) |
|
|
187 | (1) |
|
|
187 | (4) |
14 Genomic Analysis in Clinical Practice: What Are the Challenges? |
|
|
|
|
|
191 | (1) |
|
Consent for Genome Testing in Clinical Practice |
|
|
191 | (4) |
|
|
195 | (2) |
|
Management of Incidental Findings |
|
|
195 | (2) |
|
The Data Interpretation Problem |
|
|
197 | (1) |
|
What Constitutes a Result in Genomic Medicine? |
|
|
197 | (1) |
|
Diagnostic Versus Population Screening |
|
|
198 | (1) |
|
|
198 | (1) |
|
|
198 | (3) |
15 Genomic Perspective of Genetic Counseling |
|
|
|
|
|
201 | (1) |
|
Ethos and Principles of Genetic Counseling |
|
|
201 | (1) |
|
Elements of Genetic Counseling |
|
|
202 | (1) |
|
|
203 | (2) |
|
|
203 | (1) |
|
Confidentiality and Privacy of Genomic Data |
|
|
203 | (1) |
|
|
204 | (1) |
|
|
205 | (1) |
|
|
205 | (1) |
|
|
205 | (1) |
|
Practicalities of Counseling for Genomic Tests |
|
|
206 | (4) |
|
Genetic Information Is Key |
|
|
209 | (1) |
|
Patient Autonomy Must Be Supported |
|
|
210 | (1) |
|
Patient Emotions Make a Difference |
|
|
210 | (1) |
|
Relationship Is Integral to Genetic Counseling |
|
|
210 | (1) |
|
|
210 | (1) |
|
|
210 | (1) |
|
|
210 | (3) |
16 Genetics and Genomics of Reproductive Medicine and Health |
|
|
|
|
213 | (1) |
|
|
213 | (5) |
|
Congenital Anomalies of the Reproductive Tract |
|
|
213 | (1) |
|
Disorders of Abnormal Ovulation |
|
|
214 | (3) |
|
Disorders of the Endometrium |
|
|
217 | (1) |
|
|
218 | (3) |
|
Congenital Anomalies of the Male Reproductive Tract |
|
|
218 | (1) |
|
Molecular Genetics of Male Factor Infertility |
|
|
219 | (2) |
|
Mitochondrial Genes in Male Factor Infertility |
|
|
221 | (1) |
|
New Genomic Applications in Male Factor Infertility |
|
|
221 | (1) |
|
Genetic Factors in In Vitro Fertilization |
|
|
221 | (2) |
|
Preimplantation Genetic Testing and Screening |
|
|
222 | (1) |
|
Recent Advances in Prenatal Diagnosis |
|
|
223 | (1) |
|
Aneuploidy (Trisomy 21) Pregnancy |
|
|
223 | (1) |
|
|
223 | (1) |
|
|
224 | (1) |
|
|
224 | (3) |
17 Stratified and Precision Medicine |
|
|
|
|
227 | (1) |
|
Molecular, Genetic, and Genomic Revolutions in Medicine |
|
|
227 | (1) |
|
|
228 | (2) |
|
|
230 | (4) |
|
Challenges for Stratified Medicine |
|
|
232 | (1) |
|
The Future of Stratified Medicine |
|
|
233 | (1) |
|
|
234 | (1) |
|
|
234 | (3) |
18 Teaching and Training Medicine in Genomic Era |
|
|
|
|
237 | (1) |
|
Integration of Genomics into Medical Practice |
|
|
237 | (5) |
|
The Practice of Genomic Medicine |
|
|
238 | (2) |
|
The Roles of the Geneticist and Nongeneticist Health Providers |
|
|
240 | (1) |
|
Competencies Required in Genomic Medicine |
|
|
241 | (1) |
|
Genomics and the Medical Education Landscape |
|
|
242 | (1) |
|
|
242 | (1) |
|
|
242 | (1) |
|
|
242 | (1) |
|
|
243 | (1) |
|
Approaches to Medical Genomics Education |
|
|
243 | (1) |
|
|
243 | (1) |
|
|
244 | (1) |
|
Continuing Medical Education |
|
|
244 | (1) |
|
Conclusions and Final Comments |
|
|
244 | (1) |
|
|
244 | (3) |
19 Genomics, New Drug Development, and Precision Medicines |
|
|
|
|
|
247 | (3) |
|
The Drug Discovery and Development Process |
|
|
248 | (1) |
|
|
248 | (1) |
|
|
249 | (1) |
|
Applying Genomics to Drug Discovery |
|
|
250 | (3) |
|
Choosing the Best Drug Targets |
|
|
250 | (1) |
|
|
251 | (1) |
|
Single Gene Disorders/Traits |
|
|
251 | (1) |
|
Drug-Specific Targets Approach |
|
|
252 | (1) |
|
Applying Pharmacogenetics to Drug Development |
|
|
253 | (2) |
|
Pharmacodynamic Variability |
|
|
253 | (1) |
|
Pharmacokinetic Variability |
|
|
254 | (1) |
|
|
255 | (2) |
|
Predicting Type B Adverse Events |
|
|
255 | (1) |
|
Predicting Type A Adverse Events |
|
|
255 | (1) |
|
Individualized Therapy: An Integrated Response |
|
|
256 | (1) |
|
Improving Disease Classification: Stratified Medicines |
|
|
256 | (1) |
|
|
257 | (1) |
|
|
257 | (1) |
|
|
258 | (3) |
20 Cancer Genetics and Genomics |
|
|
|
|
|
261 | (1) |
|
Inherited Cancers: Germ Line and Somatic |
|
|
261 | (3) |
|
Oncogenes, Tumor Suppressor Genes, and the Identification of Cancer Predisposition Genes |
|
|
261 | (1) |
|
Identifying Cancer Predisposition Genes |
|
|
262 | (1) |
|
High, Medium, and Smaller Risks |
|
|
263 | (1) |
|
Genetic Testing in Cancer Predisposition Syndromes |
|
|
264 | (2) |
|
Risk Information as Therapy |
|
|
264 | (1) |
|
|
265 | (1) |
|
|
265 | (1) |
|
Pharmacological Management |
|
|
266 | (1) |
|
|
266 | (15) |
|
Phenotypic Effects of Mutations in Cancer Predisposition Genes |
|
|
266 | (14) |
|
Genotype-Phenotype Correlation |
|
|
280 | (1) |
|
Genetic Testing and Mainstreaming |
|
|
281 | (2) |
|
Genetic Testing and Next Generation Sequencing |
|
|
281 | (1) |
|
Reasons for Nondetection of Causative Genetic Changes Through Clinical Testing |
|
|
282 | (1) |
|
|
283 | (1) |
|
|
283 | (2) |
21 The Provision of Medical and Health Genetics and Genomics in the Developing World |
|
|
|
|
|
|
|
285 | (2) |
|
Public Health Programs in Genetics and Genomics |
|
|
287 | (3) |
|
Medical Services Incorporating Genetics and Genomics |
|
|
290 | (3) |
|
|
293 | (1) |
|
|
293 | (2) |
22 Genomic Applications in Forensic Medicine |
|
|
|
|
|
295 | (2) |
|
The Basics of Next Generation Sequencing |
|
|
297 | (2) |
|
Single Molecule Sequencing |
|
|
299 | (1) |
|
Next Generation Sequencing Solutions in Forensic Genetics |
|
|
300 | (6) |
|
Short Tandem Repeat Sequencing |
|
|
302 | (1) |
|
The First Commercial Next Generation Sequencing Kits for Forensic Genetics |
|
|
303 | (2) |
|
New Frontiers in Forensic Genetics |
|
|
305 | (1) |
|
|
306 | (1) |
|
|
307 | (1) |
|
|
307 | (4) |
23 Public and Population Health Genomics |
|
|
|
|
|
311 | (1) |
|
|
311 | (1) |
|
|
312 | (1) |
|
|
313 | (1) |
|
|
313 | (1) |
|
|
313 | (2) |
|
|
315 | (1) |
|
Cross-Cutting Issues of Population Genomics |
|
|
315 | (1) |
|
|
316 | (1) |
|
|
316 | (3) |
Glossary |
|
319 | (8) |
Index |
|
327 | |